(RTTNews) – Santhera Prescribed drugs Holding AG (SPHDF, SANN.SW), on Thursday, introduced an settlement with Biomedica Group Ltd. to distribute Agamree or vamorolone in Russia for treating Duchenne muscular dystrophy in sufferers aged 4 and above.
The gross sales are anticipated to start within the first quarter of 2026.
The corporate will obtain a proportion of internet gross sales, per prior distribution agreements.
The corporate mentioned that the partnership will broaden entry to Agamree via regional and nationwide managed entry packages, serving about 1,400 DMD sufferers throughout Russia.
Chief Government Officer Dario Eklund mentioned that it’s going to allow extra youngsters to entry this vital DMD therapy.
Agamree is a novel drug with a mode of motion primarily based on binding to the identical receptor as glucocorticoids however modifying its downstream exercise. Vamorolone is an lively pharmaceutical ingredient.
On Wednesday, Santhera Prescribed drugs closed buying and selling 0.77% lesser at CHF 10.36 on the Swiss Inventory Change.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
